These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

758 related items for PubMed ID: 22286764

  • 1. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, Hallberg B.
    Oncogene; 2012 Dec 13; 31(50):5193-200. PubMed ID: 22286764
    [Abstract] [Full Text] [Related]

  • 2. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, Thor T, Künkele A, Vandesompele J, Speleman F, Schorle H, Eggert A, Schramm A.
    Oncogene; 2013 Feb 21; 32(8):1059-65. PubMed ID: 22484425
    [Abstract] [Full Text] [Related]

  • 3. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
    Hasan MK, Nafady A, Takatori A, Kishida S, Ohira M, Suenaga Y, Hossain S, Akter J, Ogura A, Nakamura Y, Kadomatsu K, Nakagawara A.
    Sci Rep; 2013 Dec 20; 3():3450. PubMed ID: 24356251
    [Abstract] [Full Text] [Related]

  • 4. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F.
    Clin Cancer Res; 2010 Sep 01; 16(17):4353-62. PubMed ID: 20719933
    [Abstract] [Full Text] [Related]

  • 5. ALK pERKs up MYCN in neuroblastoma.
    Lindner S, Henssen A, Astrahantseff K, Schulte JH.
    Sci Signal; 2014 Oct 28; 7(349):pe27. PubMed ID: 25351246
    [Abstract] [Full Text] [Related]

  • 6. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.
    Oncotarget; 2014 Sep 30; 5(18):8737-49. PubMed ID: 25228590
    [Abstract] [Full Text] [Related]

  • 7. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
    Umapathy G, El Wakil A, Witek B, Chesler L, Danielson L, Deng X, Gray NS, Johansson M, Kvarnbrink S, Ruuth K, Schönherr C, Palmer RH, Hallberg B.
    Sci Signal; 2014 Oct 28; 7(349):ra102. PubMed ID: 25351247
    [Abstract] [Full Text] [Related]

  • 8. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ.
    Cancer Lett; 2007 Oct 28; 256(2):218-28. PubMed ID: 17643814
    [Abstract] [Full Text] [Related]

  • 9. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
    Cazes A, Lopez-Delisle L, Tsarovina K, Pierre-Eugène C, De Preter K, Peuchmaur M, Nicolas A, Provost C, Louis-Brennetot C, Daveau R, Kumps C, Cascone I, Schleiermacher G, Prignon A, Speleman F, Rohrer H, Delattre O, Janoueix-Lerosey I.
    Oncotarget; 2014 May 15; 5(9):2688-702. PubMed ID: 24811913
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M, Ribeiro D, Arsenian-Henriksson M, Deller T, Rohrer H.
    J Neurosci; 2016 Oct 05; 36(40):10425-10439. PubMed ID: 27707976
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.